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19th CardioVascular Summit: TCTAP 2014immediately after intervention for ISR. We evaluated yellow color grade (grade 0-3),
neointima coverage grade (grade 0-2), and thrombus (presence or absence) at the
culprit lesion. The patients were divided into two groups according to the maximum
yellow color grade of the lesion (White: grade 0 or 1 vs. Yellow: grade 2 or 3) and
their ISR recurrence was examined by angiography at one-year follow-up. Diameter
stenosis >50% was deﬁned as ISR.
Results: The incidence of ISR recurrencewas higher in the patientswith yellow ISR lesion
than in those with white ISR lesion (67.8% vs. 10.0%, p¼0.018). Thrombus was not
detected in both groups. Neointima coverage grade was not different between the groups.
Conclusion: The patients with yellow ISR lesion had the higher incidence of ISR
recurrence than those with white ISR lesion.
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Background: Several studies showed peri-contrast staining (PSS) was be associated
with TLR and very late stent thrombosis. However, the incidence and clinical sequela
of PSS after second generation DES implantation are unclear, so we retrospectively
evaluate the clinical outcomes.
Methods: This study consisted of de novo 1622 lesions in 1150 patients that were
treated with second generation DES (ZES, EES, and BES) in a single center. They
were evaluated by follow-up angiography within 12 months after stent implantation,
from April 2009 to August 2012. We divided into PSS group and non-PSS group and
compared the two groups in clinical and angiographical outcomes.
Results: There were no signiﬁcant differences between the two groups in patient back-
ground and lesion characteristics. Late acquired PSS was observed in 12 lesions (0.74%)
in 11 patients (0.96%). In these lesions, 2 lesions (0.63%) were observed in BES, 4 lesions
(0.4%) were EES and 6 lesions (1.9%) were ZES. (N.S.) Stent fracture was more
frequently observed in lesions with PSS than in lesions without PSS (29.4% versus 1.1%,
P <0.0001). Cumulative incidence of TLR and MACE in the PSS group was higher than
that in the non-PSS group ( 33.3% versus 5.5%, and 41.7% versus 9.6%, P <0.05).
Conclusion: In this study, PSS after second generation DES seemed to be associated
with TLR and MACE.
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Background: SF was more commonly reported in sirolimus-eluting stent (SES), right
coronary artery (RCA), longer duration of implant and longer stent length. However
the timing of stent fracture of each coronary is unknown. The purpose of this study is
to assess the time point at which SF of each coronary occurs by the multidetector
computed tomography (MDCT).
Methods: We performed 64-slice MDCT on asymptomatic and event-free 114 pa-
tients (156 lesions) who received SES implantation. These lesions are all RCA and left
anterior descending artery (LAD) to compare two coronary arteries. We investigated
the rate of SF, in-stent restenosis (ISR) and peri-stent aneurysms caused by SF. MDCT
deﬁnition of SF is complete separation or partial separation of stent struts. The average
ﬁrst CT follow-up period was 24.6months (5-75months). Then we conducted the
second MDCT 42.8 months (12-71 months) later after the ﬁrst MDCT to non-SF 45
patients (48 lesions).
Results: SF was identiﬁed in 32 lesions of 156 lesions (20.5%) at the ﬁrst MDCT. In
RCA, 14 stent fractures of 39 lesions were observed. Fracture rate was 35.8%. In
LAD, 18 stent fractures of 117 lesions were observed. Fracture rate was 15.3%. SF
was more observed in RCA than LAD at the ﬁrst MDCT (P¼0.006). ISR induced by
SF was 1 lesion (3.1%), peri-stent aneurysms were 2 lesions (6.2%). At the second
MDCT, new SF occurred in 3 lesions of non-SF 48 lesions. The rate of new SF was
6.2%. The coronary of new SF was all LAD and new SF didn’t occur at RCA. About
these 3 lesions, ISR and peri-stent aneurysm induced by SF were not detected.
Conclusion: SF was more observed in RCA than LAD at the ﬁrst MDCT, however the
newSFwas identiﬁed in onlyLAD.AboutLAD, it is possibility to increase the rate ofSF in
chronic phase. We continue to follow up the patients who received SES implantation.S20 JACC Vol 63/12/Suppl STCTAP A-069
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Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small coronary
vessels (reference vessel diameter <2.5 mm) were submitted to PCI. Biolimus-eluting
stent (BES) was deployed at a low pressure with long inﬂation time.
Results: Two cases of distal edge dissection were observed and one of them needed
additional stent implantation. Postprocedural TIMI grade 3 ﬂows were achieved in all
patients. There were no death, myocardial infarction (MI) and target lesion revascular-
ization (TLR) during the initial hospitalization. The angiographic data is shown in
Figure. Average luminal diameters(ALD) in distal segments signiﬁcantly increased from
baseline (1.360.49 mm vs. 1.560.31, p<0.01). At 12 months after procedure, the rate
of TLR was 8.0%. There were no cardiac death and MI related to target lesions. Distal
ALD tended to increase from initial procedure (1.710.30mm, p¼0.07).
Conclusion: BES implantation to very small coronary vessels achieved a high clinical
success and luminal diameter distal to stent signiﬁcantly increased and remained
unchanged at 12-month follow-up.TCTAP A-070
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Background: Stent thrombosis has been strongly associated with discontinuation of
dual antiplatelet therapy. The central point of stent thrombosis seems to be the
impaired, or delayed re-endothelialization, and the most important histological and
morphometric predictors of late stent thrombosis (LST) were endothelial coverage and
the ratio of uncovered to total stent struts after drug-eluting stent (DES) implantation.
However, recent controversies regarding the risk of stent thrombosis in patients receiving
DES has brought up the issue of the appropriate duration of antiplatelet therapy after
percutaneous coronary intervention, and a recent study reported that the use of extended
DAPT for a period longer than 12 months in patients who had received DES was not
signiﬁcantly more effective than aspirin monotherapy in reducing the rate of MI or death
for cardiac causes. While second generation DES promote more favorable vascular
healing comparing to ﬁrst generation DES, biodegradable polymer containing stents
might have a yield in terms of duration of dual antiplatelet therapy (DAPT) than durable
polymer stents. We aimed to test whether biolimus-eluting stent (BES) with 6-month
DAPT would be non-inferior 12-month clinical and angiographic outcome to Zotar-
olimus-eluting stent (ZES) with 6-month DAPT.
Methods: This is a prospective, randomized, open-label, multicenter trial to compare
clinical events and angiographic data between BES and ZES stents. Currently, 621
patients were randomly assigned. The primary end point was a major adverse cardiac
events (MACE) at 12 months. Optical coherence tomography (OCT) at 6 month was
performed in 30 patients of each group. The primary endpoint was MACE, secondary
end points are target lesion failure, in-segment late loss (LL) at 12 months, and
neointimal hyperplasia (NIH) and uncovered stent strut (%) by OCT at 6month.
Results: Currently, clinical follow-up was available in 325 patients and angiographic
follow-up in 311 patients. The primary endpoints were not statistically differentj April 22–25, 2014 j TCTAP Abstracts/ORAL/Drug-eluting Stents
